321 related articles for article (PubMed ID: 33687951)
41. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.
Dibra D; Mitra A; Newman M; Xia X; Cutrera JJ; Gagea M; Kleinerman ES; Lozano G; Li S
Clin Cancer Res; 2016 Aug; 22(15):3876-83. PubMed ID: 26979394
[TBL] [Abstract][Full Text] [Related]
42. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
43. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
[TBL] [Abstract][Full Text] [Related]
44. [Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant].
Tsuchiya K
Hokkaido Igaku Zasshi; 2000 Jul; 75(4):265-74. PubMed ID: 10976406
[TBL] [Abstract][Full Text] [Related]
45. p53-mediated regulation of cell cycle progression: pronounced impact of cellular microenvironment.
Schmid G; Kramer MP; Wesierska-Gadek J
J Cell Physiol; 2009 May; 219(2):459-69. PubMed ID: 19170070
[TBL] [Abstract][Full Text] [Related]
46. Crippling p53 activities via knock-in mutations in mouse models.
Iwakuma T; Lozano G
Oncogene; 2007 Apr; 26(15):2177-84. PubMed ID: 17401426
[TBL] [Abstract][Full Text] [Related]
47. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
48. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
49. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
50. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
51. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis.
Iozzo RV; Chakrani F; Perrotti D; McQuillan DJ; Skorski T; Calabretta B; Eichstetter I
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3092-7. PubMed ID: 10077642
[TBL] [Abstract][Full Text] [Related]
52. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
[TBL] [Abstract][Full Text] [Related]
53. Allele-specific p53 mutant reactivation.
Yu X; Vazquez A; Levine AJ; Carpizo DR
Cancer Cell; 2012 May; 21(5):614-625. PubMed ID: 22624712
[TBL] [Abstract][Full Text] [Related]
54. The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells.
Almog N; Li R; Peled A; Schwartz D; Wolkowicz R; Goldfinger N; Pei H; Rotter V
Mol Cell Biol; 1997 Feb; 17(2):713-22. PubMed ID: 9001225
[TBL] [Abstract][Full Text] [Related]
55. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
56. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.
Bykov VJ; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
J Biol Chem; 2005 Aug; 280(34):30384-91. PubMed ID: 15998635
[TBL] [Abstract][Full Text] [Related]
57. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
58. Selective protection of non-cancer cells by hypothermia.
Matijasevic Z
Anticancer Res; 2002; 22(6A):3267-72. PubMed ID: 12530074
[TBL] [Abstract][Full Text] [Related]
59. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
Liu W; Ip MM; Podgorsak MB; Das GM
Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
[TBL] [Abstract][Full Text] [Related]
60. Stable expression of temperature-sensitive p53: a suitable model to study wild-type p53 function in pancreatic carcinoma cells.
Nuevemann D; Christgen M; Ungefroren H; Kalthoff H
Oncol Rep; 2006 Sep; 16(3):575-9. PubMed ID: 16865258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
